COMP <GO>
MOBI vs CLPT // DIVIDEND YIELD & FCF PAYOUT SAFETY
Mobia Medical Inc. (NASDAQ) VS. ClearPoint Neuro Inc. (NASDAQ) • 15-METRIC TALLY: MOBI 2
— CLPT 0
■ METRIC PARITY
LAST: $11.27 (-4.41%) • MKT CAP: $375.2M
dividend-safety
0.00%
LAST: $10.69 (+1.23%) • MKT CAP: $342.7M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOBI VS. CLPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOBI | CLPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 61.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -7.13% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 17.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 48.9 | +7.22 | MOBI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $375.2M | $342.7M | $32.5M | MOBI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOBI REV | CLPT REV | MOBI GROSS % | CLPT GROSS % | MOBI FCF | CLPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $37.0M | — | 61.4% | — | -$24.4M |
| FY 2024 | — | $31.4M | — | 60.9% | — | -$9.2M |
| FY 2023 | — | $24.0M | — | — | — | -$13.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOBI // BETA —
CLPT // BETA —